Evidence Against Routine Use of Glucagon for Prostate MRI
Radiology: Imaging Cancer · 2023
DOI: 10.1148/rycan.230053 ↗Kurz gefasst
Kommentar in der Zeitschrift Radiology: Imaging Cancer, 2023. Verfasst von Steven C Eberhardt. Beteiligte Einrichtung: From the Department of Radiology, University of New Mexico, MSC10 5530, 1 University of New Mexico, Albuquerque, NM 87131. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Radiology, University of New Mexico, MSC10 5530, 1 University of New Mexico, Albuquerque, NM 87131.
ORCID-Profile: Steven C Eberhardt
Zitieren
APA
Eberhardt, S. C. (2023). Evidence Against Routine Use of Glucagon for Prostate MRI. Radiology: Imaging Cancer. https://doi.org/10.1148/rycan.230053
Vancouver
Eberhardt SC. Evidence Against Routine Use of Glucagon for Prostate MRI. Radiology: Imaging Cancer. 2023. doi:10.1148/rycan.230053
BibTeX
@article{Eberhardt2023,
author = {Eberhardt, Steven C},
title = {Evidence Against Routine Use of Glucagon for Prostate MRI},
journal = {Radiology: Imaging Cancer},
year = {2023},
doi = {10.1148/rycan.230053}
}
EUVIMED